BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- ...

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

Age-Related Macular Degeneration market growth analysis. PORTLAND, OR, UNITED STATES, November 21, 2024 /EINPresswire / -- Increase in prevalence of age-re ...

Eyes with neovascular age-related macular degeneration (nAMD) with different macular neovascularization subtypes show distinct retinal fluid volume dynamic responses to anti-angio ...

Diabetic retinopathy (DR) is the primary cause of visual impairment among working-age populations in industrialized nations.

More injections generally deliver better outcomes ... registry that started VEGF inhibitors (aflibercept, ranibizumab or bevacizumab) in Australia between July 2018 and April 2023, when detailed ...

Lipotropic injections contain vitamins and nutrients that some people believe may support weight loss. Side effects can vary based on the ingredients of the injection. Lipotropic injections are ...

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...

Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations.

New Delhi: The drug major Sun Pharmaceutical Industries has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the ...